Andere talen OmniAb, Inc.

Aandelen

OABI

US68218J1034

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 10-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4,68 ^USD	+2,41%		+0,21%	-24,15%

09/05	OmniAb, Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
09/05	Transcript : OmniAb, Inc., Q1 2024 Earnings Call, May 09, 2024

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Earnings Flash (OABI) OMNIAB Reports Q1 Revenue $3.8M, vs. Street Est of $5.9M	09/05
OmniAb, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
OmniAb Reports First Quarter 2024 Financial Results and Business Highlights	09/05
OmniAb to Participate in Five Investor Conferences in May	01/05
OmniAb to Report First Quarter 2024 Financial Results on May 9	22/04
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate Biotherapeutics	16/04
OmniAb : March 2024 Corporate Overview	26/03
OmniAb Insider Bought Shares Worth $1,167,750, According to a Recent SEC Filing	25/03
Sector Update: Health Care Stocks Gain Pre-Bell Thursday	21/03
OmniAb Swings to Q4 Loss, Revenue Declines	20/03
Earnings Flash (OABI) OMNIAB Posts Q4 Revenue $4.8M, vs. Street Est of $7.46M	20/03
OmniAb, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20/03
OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	20/03
OmniAb to Report Fourth Quarter 2023 Financial Results on March 20	26/02
OmniAb to Participate in Two Investor Conferences in March	20/02
OmniAb, Inc.(NasdaqGM:OABI) added to NASDAQ Biotechnology Index	18/12
OmniAb Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering and Therapeutics Conference	15/12
OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics Conference	14/12
OmniAb, Inc. Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference	14/12
Omniab Insider Bought Shares Worth $1,010,000, According to a Recent SEC Filing	13/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen OmniAb, Inc.

Aandelen

OABI

US68218J1034

Andere talen

Filters